These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://roxannyrae915031.blogstival.com/60581737/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide